- CSL’s full year net profit after tax was $1.73 billion, up 28%.
- Revenue was $7.9 billion, up 11%.
- The full year dividend was $1.72 per share, up 26%
Blood products group CSL posted a 28% rise in full year net profit after tax to $1.73 billion, partly due to a tightness in supply of plasma and a lift in sales of ‘flu vaccines.
In early trade, CSL shares were up about $2.45, or 1.2%, to $204.14.
“The strength of our results reflects the execution of our strategy and patient-focused workforce,” says Paul Perreault, CSL’s Chief Executive Officer and Managing Director.
“The tightness in supply of our key raw material, plasma, has been a feature across the industry this year.
“The CSL Plasma team have opened 27 new collection centres in the US — a growth rate unmatched in the industry. CSL now operates 206 plasma collection centres worldwide.”
The biotech says seasonal influenza vaccine sales were up 53%.
The company expects net profit after tax for 2019 to be in the range of $1.88 billion to $1.95 billion, representing growth of 10% to 14%.
The 2018 results at a glance:
NOW WATCH: Money & Markets videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.